A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
This is a study of oral LY2157299 as monotherapy and in combination with lomustine in participants with recurrent malignant glioma.
Glioma
DRUG: LY2157299|DRUG: Lomustine
Recommended Dose for Phase 2 Studies, Time of first dose to time of last dose (estimated up to 8 years)
Number of Participants with Tumor Response, Time of first dose to time of last dose (estimated up to 8 years)|Biologically Effective Dose Range, Baseline, Days 1, 12, 13 of Cycle 1, Days 1 and 12 of Cycle 2 of Part A - LY2157299 as monotherapy|Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC), Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14|Pharmacokinetics (PK): Maximum Concentration (Cmax), Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14
This is a study of oral LY2157299 as monotherapy and in combination with lomustine in participants with recurrent malignant glioma.